A number of other research analysts have also recently commented on CTMX. Mizuho initiated coverage on shares of CytomX Therapeutics in a report on Wednesday, June 12th. They issued a “buy” rating and a $16.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $23.00 price objective (up previously from $21.00) on shares of CytomX Therapeutics in a research note on Monday, June 3rd. Nomura lowered their price objective on CytomX Therapeutics to $22.00 in a research note on Monday, May 13th. HC Wainwright reaffirmed a “buy” rating and issued a $1.75 price objective on shares of Orion Energy Systems in a research note on Wednesday, April 3rd. Finally, ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $20.72.
CTMX stock opened at $11.82 on Friday. The company has a market capitalization of $535.56 million, a PE ratio of -5.82 and a beta of 0.64. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.21 and a quick ratio of 4.21. CytomX Therapeutics has a 12 month low of $8.94 and a 12 month high of $27.20. The business has a 50-day moving average of $10.75.
Several institutional investors have recently added to or reduced their stakes in CTMX. BNP Paribas Arbitrage SA increased its stake in shares of CytomX Therapeutics by 84,072.7% in the first quarter. BNP Paribas Arbitrage SA now owns 9,259 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 9,248 shares during the period. Legal & General Group Plc increased its position in CytomX Therapeutics by 18.6% during the 4th quarter. Legal & General Group Plc now owns 8,342 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 1,306 shares during the period. Deltec Asset Management LLC acquired a new stake in CytomX Therapeutics during the 1st quarter valued at approximately $129,000. Metropolitan Life Insurance Co. NY increased its position in CytomX Therapeutics by 376.5% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,479 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 10,650 shares during the period. Finally, First Trust Advisors LP acquired a new stake in CytomX Therapeutics during the 1st quarter valued at approximately $263,000. 81.83% of the stock is owned by institutional investors.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Recommended Story: Why is total return important?
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.